NCT03536117 - Dose-Defining Safety and Immunogenicity Study of MTBVAC in South African Neonates | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 12, 2019

Primary Completion Date

May 17, 2022

Study Completion Date

May 17, 2022

Conditions

Tuberculosis

Interventions

BIOLOGICAL

MTBVAC

Live-attenuated Mycobacterium tuberculosis based on the deletion of phoP and fadD26 virulence genes

BIOLOGICAL

BCG

Live-attenuated Mycobacterium bovis obtained by subculture passaging in ox-bile and glycerated potatoes between 1908-1921 by Albert Calmette and Camille Guerin. BCG is the only licensed vaccine today against tuberculosis (TB) mainly used in TB-endemic countries.

Trial Locations (1)

6850

SATVI: Worcester, Worcester